Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral Baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
January 2025
in “
The Egyptian Journal of Hospital Medicine
”
TLDR Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
The study evaluated the efficacy and safety of oral baricitinib, a JAK inhibitor, alone and in combination with topical tacrolimus for treating localized stable vitiligo in 10 adult patients. Over 24 weeks, significant repigmentation was observed in all lesions, with greater improvement in those also treated with topical tacrolimus. The improvement rate was 77% for oral therapy alone and 82% for the combination, though the difference was not statistically significant (P=0.177). Only 2 patients were unsatisfied with the oral therapy alone, with no significant dissatisfaction (P=0.5). The study concludes that baricitinib is effective and safe as a monotherapy or combined with topical tacrolimus for treating localized vitiligo.